Showing results (81-90 of 87) with videos related to
Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 87 results.
The Lancet. Oncology|October 8, 2013
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trialAndré Robidoux, Gong Tang, Priya Rastogi, et al.The Lancet. Oncology|August 15, 2015
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trialHarry D Bear, Gong Tang, Priya Rastogi, et al.The New England Journal of Medicine|January 27, 2012
Bevacizumab added to neoadjuvant chemotherapy for breast cancerHarry D Bear, Gong Tang, Priya Rastogi, et al.Annals of Surgical Oncology|November 20, 2016
The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40Harry D Bear, Gong Tang, Priya Rastogi, et al.Journal of the National Cancer Institute|September 10, 2024
Quality-of-life outcomes from NRG Oncology NSABP B-39/RTOG 0413: whole-breast irradiation vs accelerated partial-breast irradiation after breast-conserving surgeryPatricia A Ganz, Reena S Cecchini, Julia R White, et al.Lancet (London, England)|December 10, 2019
Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trialFrank A Vicini, Reena S Cecchini, Julia R White, et al.Cancer Cell|February 11, 2025
Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtypingCarsten Denkert, Sivaramakrishna Rachakonda, Thomas Karn, et al.Pageof 9